Coexistence of pyoderma gangrenosum and sweet’s syndrome in a patient with ulcerative colitis

Coexistence of pyoderma gangrenosum and sweet’s syndrome in a patient with ulcerative colitis

 

Faida Ajili^1,&, Asmahan Souissi², Fathi Bougrine³, Najah Boussetta¹, Nadia Ben Abdelhafidh¹, Sameh Sayhi¹, Bassem Louzir¹, Nejib Doss², Janet Laabidi¹, Salah Othmani¹

 

¹Department of Internal Medicine, Military Hospital of Tunis, 1008 Montleury, Tunisie, ²Department of Dermatology, Military Hospital of Tunis, 1008 Montleury, Tunisie, ³Department of Anatomopathology, Military Hospital of Tunis, 1008 Montleury, Tunisie

 

 

^&Auteur correspondant
Faida Ajili, Department of Internal Medicine, Military Hospital of Tunis, 1008 Montleury, Tunisie

 

 

 

 

Neutrophilic dermatoses (NDs) are characterized histologically by an epidermal and/or dermal infiltrate of polymorphonuclear leucocytes, absence of microorganisms on special stains and culture. This group of diseases includes, Sweet´s syndrome (SS), pyoderma gangrenosum (PG), erythema elevatum diutinum, neutrophilic eccrine hidradenitis and Sneddon Wilkinson disease [1]. Recently, NDs have been included among the autoinflammatory diseases, which are due to mutations of genes regulating the innate immune responses [2]. These entities are distinguished by the existence of forms of transition or overlap and the frequency of their association with systemic diseases especially hematologic and gastrointestinal ones. We report a case of a patient with ulcerative colitis (UC) who successively developed two types of NDs: PG then SS.

 

 

A 66 year old patient with a history of UC treated by mesalazine since 5 years consulted in July 2012 for a painful erythematous swelling of the back of the right hand. The bacteriological samples were negative, the lesion was considered as an abscesses and the patient was treated with antibiotics and local antiseptics without improvement. The evolution was characterized by the appearance of an erythematous vesiculobullous centrifugal expansion taking the whole back of the right hand treated several times by various antibiotics unsuccessfully. Biopsy of this lesion was initially not specific. In October 2012, the patient was hospitalized for fever and polyarthralgia in the context of impaired general condition. He had a quiescent UC disease.

 

The skin examination found an erythematous plaque of 10 cm of diameter, with a raised border and vesicules, taking the back of the right hand and wrist (Figure 1) . There was also an infiltrated erythematous plaque on the right leg (Figure 2) and another topped with a large pustule at the left ankle (Figure 3). In biology, there was a biological inflammatory syndrome and high leukocytosis with neutrophils. Hepatic and renal functions were normal. Skin biopsy showed at the edge of the back of the closet right hand ulcerated epidermis and the dermis infiltrate rich in neutrophils with leukocytoclastic vasculitis finding a PG (Figure 4). Other biopsies taken at infiltrated erythematous plaques of the ankle showed a normal appearance of skin, edema of the superficial dermis based on an infiltrate rich in neutrophils without vasculitis confirming the diagnosis of SS (Figure 5). Corticosteroid treatment was then started with prednisolone at a dose of 1mg/Kg/j. The evolution was marked since day 7 of treatment by the desinfiltration of the plaques (Figure 6), the recovery of the general condition and disappearance of biological inflammatory syndrome.

 

 

SS and PG are the most common neutrophilic dermatosis. They have many features in common: neutrophilic infiltrate, altered immunologic reactivity, response to immunosuppressives and reports of coexistence in a single patient [3]. The combination of these two entities has already been described in cases of hematologic and much more rarely in the case of chronic inflammatory bowel disease [4] .In fact , there is an overlap between the two conditions with lesions categorised as SS actually being clinically more characteristic of atypical bullous PG and vice versa [3]. Indeed, a typical lesion initially of SS can evolve to a future PG.

 

Other associations of NDs have been reported: PG and subcorneal pustular dermatosis [5], PG and aseptic spleen abscess [6]. We are actually dealing with a "neutrophilic disease". Our observation showed that neutrophilic dermatoses are a continous spectrum as our patient developed first PG followed by SS. Unlike PG, the incidence of which, in UC patients, is about 1-3% [2], SS is very rare. The increasing number of patients affected by intestinal bowel diseases (IBD) developing SS during the last years, together with the evidence that cutaneous manifestations of IBD are very frequent, would appear to suggest that there is a relationship, possibly a common pathogenetic mechanism, between IBD and SS. Although NDs have been described also in some patients with quiescent IBD, the occurrence of the disorder has frequently been reported during relapse of disease. The patient described here had a quiescent disease when the NDs had occurred.

 

In histological samples, the lack of vasculitis and the abrupt onset of dermatosis without ulcerations allow the SS to be dinguished from PG. Malone et al suggested that vasculitis may be present in some patients with Sweet's syndrome. It is than an epiphenomen due to the release of noxious products from neutrophils, especially in the cases of lesions of long duration [7]. In our patient, histology was typical for PG and SS without vasculitis in the second one.

 

Concerning the treatment of NDs, usually four to six weeks of glucocorticoid therapy are needed [2]. Agents that have been successfully implemented as glucocorticoid-sparing agents include dapsone, azathioprine [8, 9], tacrolimus, mycophenolate mofetil, methotrexate, chlorambucil, and clofazimine [2]. Tumor necrosis factor-α inhibitors, such as adalimumab or infliximab, have been shown to be helpful with refractory disease, especially in patients with inflammatory bowel disease [10]. SS and PG are usually responsive to oral corticosteroids, and the immunosuppressant should be considered in resistant or highly relapsing cases. In our case, the UC was quiescent so our patient was treated with corticoids alone with a good clinical and biological evolution.

 

 

PG and SS are distinguished by the existence of forms of transition or overlap. They are frequently associated to systemic diseases especially hematologic and gastrointestinal ones. Our observation demonstrated that neutrophilic dermatoses form a continous spectrum of entities that may occur in UC.

 

 

The author's declare no competing interests.

 

 

All authors contributed significantly to this work.

 

 

Figure 1: erythematous plaque with vesicular bubbles, elevated edge, interesting the back of the right hand and wrist

Figure 2: an infiltrated erythematous plaque on the right leg

Figure 3: infiltrated erythematous plaque of the left ankle surmounted by a large pustule

Figure 4: pyoderma gangrenosum: dermal polynuclear suppuration with vasculitis: (HE x 200)

Figure 5: papillary dermal edema and intense dermal neutrophilic infiltrate with leucocytoclasia without vasculitis

Figure 6: early desinfiltration and healing in day 7 of treatment with regression of bubbles

 

 

1. Vázquez García J, Almagro Sánchez M, Fonseca Capdevila E. Multiple neutrophilic dermatoses in myelodysplastic syndrome . Clinical and Experimental Dermatology. 2001; 26(5): 398-401. PubMed | Google Scholar


2. Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013; 45(2):202-10. PubMed | Google Scholar


3. Lear JT, Atherton MT, Byrne JPH. Neutrophilic dermatoses: pyoderma gangrenosum and sweet's syndrome. Postgrad Med J.1997; 73(856):65-8. PubMed | Google Scholar


4. Ahmad K, Ramsay B. Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol. 2009;34(1):46-8. PubMed | Google Scholar


5. Brahimi N, Maubec E, Palazzo E, Larger E, Mohammedi K, Landry J et al. Pyoderma gangrenosum with aseptic spleen abscess. Ann Dermatol Venereol. 2009;136 (1):46-9. PubMed | Google Scholar


6. Malone JC, Slone SP, Wills-Frank LA, Fearneyhough PK , Lear SC , Goldsmith U et al. Vascular inflammation (vasculitis) in Sweet syndrome. Arch Dermatol. 2002;138 (3): 345-9. PubMed | Google Scholar


7. Shankar S, Sterling JC, Rytina E. Pustular pyoderma gangrenosum. Clin Exp Dermatol. 2003; 28 (6):600-3. PubMed | Google Scholar


8. Javaid B. Pyoderma gangrenosum in Crohn's disease, unusual presentation and management. Case Rep Gastroenterol. 2009; 3(3):50-3. PubMed | Google Scholar


9. Fonder MA et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006; 20;5:e8. PubMed | Google Scholar


10. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis: case report and literature review. Dermatology. 2007;215(3):245-51. PubMed | Google Scholar